Letrozole

Letrozole is primarily used in clinical settings for the treatment of hormone receptor-positive breast cancer, especially in postmenopausal women. It works as an aromatase inhibitor, effectively lowering estrogen levels and thus slowing the growth of estrogen-dependent tumors.

Breast Cancer:

• Metastatic Breast Cancer: Letrozole is often used for locally advanced or metastatic breast cancer in postmenopausal women. A completed Phase 2 trial (NCT01231659) explored the safety and efficacy of Letrozole in combination with Everolimus, showing promise in such treatments.
• Early-Stage Breast Cancer: Letrozole can also be considered in early-stage breast cancer. A Phase 4 trial (NCT03948568) evaluated the timing of endocrine and radiation therapy in these patients, highlighting Letrozole's role in managing early-stage disease.

Precocious Puberty:

• McCune Albright Syndrome: In a completed Phase 1 trial (NCT00006174), Letrozole was tested for its effects on precocious puberty due to McCune Albright Syndrome, showing potential utility beyond cancer treatment.

Polycystic Ovarian Syndrome (PCOS):

• A study in the International Journal of Women's Health analyzed Letrozole among other medications for PCOS, providing insights into its application in this condition, though direct conclusions on efficacy in PCOS are limited.

Pharmacovigilance and Safety:

• Concerns about letrozole-related hepatotoxicity were assessed in a study published in MRCAS, utilizing pharmacovigilance data to detect potential adverse hepatic events associated with its use.

Letrozole has been a mainstay in hormone therapy for specific cancers due to its efficacy in reducing estrogen levels and impacting tumor growth, with ongoing research further exploring its broader applications and safety profile.

Disclaimer: This information is not a substitute for professional medical advice. Always consult healthcare professionals for medical decisions.